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FUNDING Hologic (Inc. Bedford, MA, USA) offered the test kits for E6/E7 viral mRNA detection of 14 high risk HPV types (APTIMA 
assay). There was no other funding.
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ABSTRACT
Background. Screening for anal dysplasia in human immunodeficiency virus (HIV)-infected patients is not standardized. High-
resolution imaging is not adequate for mass screening, and anal cytology requires expertise. New biomarkers, selected because of 
their use in cervical cancer mass screening, have been originally tested for targeted and easy-to-perform screening. Methods. 120
HIV-infected individuals (males 96.4%, mean age 47±11 years) were referred for clinical examination, anoscopy, and cytological 
studies on anal swab. Dysplasia grading, Human Papilloma Virus genotyping, E6/E7mRNA detection and p16INK4A/Ki-67
immunostaining were performed. High-grade lesions were histologically confirmed by anal biopsies after high-resolution anoscopy. 
Results. Among the 120 anal swabs analysed, 36 (30%) had low grade, and 6 (5%) had high-grade lesions. Virus genotype was 
identified in 88 patients (73.3%), and 77 (64.2%) were positive for high-risk genotype(s). High-risk genotype was associated to low-
grade or high-grade lesions with a sensitivity of 0.93, and a specificity of 0.51. For E6/E7mRNA, sensitivity and specificity for low-
grade and high-grade lesions were, respectively, 0.88, and 0.78. Combination of genotyping, E6/E7mRNA and p16INK4A/Ki-67 
appropriately ruled out dysplasia in 55% of patients. Conclusions. Three routine biomarkers may avoid unnecessary invasive 
procedures with the perspective of an improvement of patient compliance. A decision making algorithm, based on the combination 
of these 3 biomarkers, is proposed.
Key Words: HIV, HPV, anal dysplasia, high-risk HPV genotypes, high-risk HPV E6/E7 mRNA, p16 INK4A/Ki-67
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INTRODUCTION
The incidence of anal cancer has dramatically increased over the last decade in high-risk groups, including men who have sex with 
men (MSM), women with a previous history of cervical or vulvar cancer, and immunocompromised patients, especially those who 
are Human Immunodeficiency Virus (HIV)-infected (1-4). Several series estimated that the risk of anal cancer in HIV-infected MSM 
is comparable to the risk of cervical cancer in the general female population (5, 6). As for cervical cancers, intra-epithelial lesions 
induced by human papillomavirus (HPV) precede invasive anal cancer. Studies on the prevalence of HPV and its association to 
dysplasia in anal samples have demonstrated that both HPV and cytological abnormalities are common in high-risk populations. 
The overall prevalence of HPV infection in anal carcinoma was estimated at 85-97%, HPV-16 being the most frequent genotype, 
found in ~75% of cases (7, 8). Studies based on systematic cytology of anal swabs yield a much greater burden of abnormal 
findings than studies based on biopsies restricted to macroscopic lesions. In a large prospective study of HIV-infected MSM, the 
incidence of anal intra epithelial neoplasm was 37% over a 3-year period (9). The prevalence of abnormal cytology ranges from 
30% to 67% in these populations, and high-grade squamous intra-epithelial lesions (H-SIL) are found in 5-24%.
These data advocate for the implementation of systematic screening for anal neoplasia in specific groups (4, 10). However, 
screening for anal dysplasia in high-risk populations is neither universally recommended, nor standardized. French guidelines 
recommend annual anoscopy in HIV-infected MSM, and in HIV-infected women with HPV-related genital lesions, and encourages 
systematic cytological studies of anal swabs during these screening (11), but these recommendations are poorly implemented for 
the following reasons: i) the number of specialized clinics offering expert evaluation and anoscopy is not sufficient in most areas; ii)
this invasive procedure may be poorly tolerated by patients, and time-consuming for proctologists; iii) most pathologists are not 
familiar with anal cytology. In addition, both methods (i.e. anoscopy and cytological studies on anal swab) have questionable 
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reproducibility and sensitivity to detect dysplasia of the anal canal. Testing several biomarkers, Wentzensen et al. found that HPV 
DNA genotyping and p16/Ki-67 on anal swabs had the highest sensitivity (92-100%) for the detection of anal dysplasia in high-risk 
patients (12). In order to improve the efficiency of screening programs, the aims of the present study were two-fold: i) to evaluate 
the diagnostic accuracy of these biomarkers, and ii) to determine their potential use for targeted screening of anal dysplasia in HIV-
infected patients.
MATERIALS AND METHODS
Study design. This cross-sectional study was conducted in the Rennes University Hospital, a tertiary care teaching hospital which 
serves as the referral centre for HIV-infected patients, and for anal pathology in the area (Western France, catchment population 
estimated at one million inhabitants). All HIV-infected patients were invited for anal neoplasia screening at the department of 
proctology, with special emphasis in MSM and women with HPV-related genital lesions, according to national guidelines. The first 
visit consisted in clinical examination, digital rectal examination, anoscopy, and collection of anal swabs for cytological studies. Data 
about life style and HIV disease were collected using a standardized questionnaire: gender, age, sexual activity, past history of 
sexually transmitted infection(s), and HIV-related parameters, including CDC stage, antiretroviral treatment (ART), CD4 cell counts, 
and HIV viral load. Before anos opy, two Dacron swabs were collected from the anal canal and immediately suspended into 
ThinPrep PreservCyt medium (Hologic, Inc. Bedford, MA, USA): one was sent for cytology and immunohistochemistry studies, the 
other one for virological analysis. Specimens were maintained at +4°C before processing for analyses or aliquoted and stored at -
80°C. All patients diagnosed with abnormal cytology through this first step underwent high-resolution anoscopy (HRA), and guided-
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biopsies were performed for histological studies if lesions were suspected, using acetic acid and Lugol’s solution for better 
visualization. No biopsy was obtained from patient with normal cytology. 
Cytology and histology. Two slides were prepared with the same medium. One was stained for cytology and the other one 
for immunochemistry. The pathologist who analysed samples has a long-standing experience in the analysis of anal samples, and 
was blinded to the results of biomarkers (HPV genotype, HPV E6/E7 mRNA and p16/Ki-67). Cytology grades were reported 
according to the Bethesda classification: no intraepithelial lesion (NIL), atypical squamous cell of undetermined significance (ASC-
US), low-grade or high-grade squamous intraepithelial lesions (L-SIL or H-SIL) (13). The same pathologist classified histology as 
normal, low- or high-grade intra-epithelial lesions.
p16INK4A/Ki-67 dual staining. All specimens were tested for dual immunostaining p16INK4A/Ki-67 CINtec® PLUS (Roche, 
MTM laboratories AG, Heidelberg, Germany), according to the manufacturer’s instructions. Protein p16 INK4A is a cell cycle 
regulatory protein overexpressed in high risk (hr) HPV persistent infection, and Ki-67 is a proliferation marker. The kit is a 
combination of two antibodies against p16INK4A and Ki-67 used in the same slide, with different chromogens. The presence of at 
least one double-stained cell is interpreted as a positive test. 
HPV DNA detection and genotyping. DNA testing was performed using the PreservCyt medium: 200 ?L were used for 
DNA extraction on MagNA Pure LC (Roche, Bâle, Switzerland). Anal specimens were tested for 35 HPV genotypes with CLART 
Human Papillomavirus 2 (Genomica, Madrid, Spain), a commercial kit for the detection of 15 low risk (lr) HPV (6, 11, 40, 42, 43, 44, 
54, 61, 62, 71, 72, 81, 83, 84, 89), and 20 high risk (hr) HPV (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 
82, 85). The tests included a cellular control and an internal control. Microarray studies were analyzed using Clinical Arrays Reader 
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(Genomica). A sample of 2 mL of each liquid-based medium was then frozen at -80°C. A hr-HPV DNA test was considered positive 
if at least one hr-HPV genotype was detected.
High-risk (hr) HPV E6/E7 mRNA detection. Specimens were tested for E6/E7 mRNA using HPV APTIMA assay (Hologic) 
on the PANTHER System, which detects E6/E7 viral mRNA of 14 hr-HPV types collectively by transcription-mediated amplification 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68). An aliquot of 1 mL of each sample was transferred into the APTIMA transfer 
tube and introduced into the PANTHER system without any other manipulation. According to the manufacturer’s instructions, a 
cervix sample specimen is considered positive when the value of the signal-to-cut-off ratio (S/CO) is >1. Because there is no 
validated S/CO threshold for anal samples, we reported the quantitative result of the hr-HPV E6/E7 mRNA test, and empirically 
used a conservative S/CO ratio threshold of 6. To validate this threshold, we tested HPV DNA negative samples and found that 
they all were either negative for hr-HPV E6/E7 mRNA, or had a S/CO ratio < 6. 
Ethics. The database was authorized by the national regulatory institution, Commission Nationale Informatique et Liberté
(CNIL n°1412467), and the study was approved by our institutional review board (N09-14). All participants provided written informed 
consent. 
Statistical analysis. Mean and standard deviation were used to describe quantitative variables; number and percentage 
were used to describe qualitative variables. Differences between groups were measured using non-parametric tests where 
appropriate (Wilcoxon, Pearson, Chi2 or MacNemar). A P value <0.05 was considered significant. The performance of p16INK4A/Ki-
67 dual staining, hr-HPV DNA, and hr-HPV E6/E7 mRNA for the diagnosis of L-SIL and H-SIL was estimated. Statistical analyses 
were performed using JMP® Pro 9.0.2, 2010 (SAS Institute Inc., Cary, North Carolina, USA).
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RESULTS
Study participants. Between October 2010 and November 2011, 120 HIV-infected patients were enrolled in this cross-sectional 
study. The main characteristics of the study population are summarized in Table 1. The mean age was 47±11 years (range, 21-79). 
Among the 108 men, 89 (82.4%) were MSM. All patients underwent a clinical examination of the peri-anal skin and anal canal 
through an anoscope. Macroscopic signs of HPV infection were observed in 20 patients (16.7%), including external condyloma 
(n=12), and/or endocanal lesions (n=13). There was no ulceration and no clinical cancer. 
Cytological findings. Among the 120 anal swabs analyzed, 51 (42.5%) yielded NIL, 27 (22.5%) ASC-US, 36 (30%) L-SIL, 
and 6 (5%) H-SIL. All patients with a cytological diagnosis of H-SIL were histologically confirmed, with high-grade intra-epithelial 
dysplasia identified through HRA-guided biopsies. No invasive cancer was diagnosed at baseline. 
HPV DNA genotyping, hr-HPV E6/E7 mRNA detection, and p16INK4A/Ki-67 dual staining. HPV genotype was identified in 
88 patients (74.6%), no HPV was found in 30 patients (25.4%), and HPV was detected, but could not be genotyped in the remaining 
two patients (both had NIL). Table 2 highlights the prevalence of high risk genotypes according to the cytological status. The 
following genotypes were the most common that differed according to cytological status: 16, 31, 35, 51, 52. Table 3 summarizes the 
mean number of different genotypes and the prevalence of hr-HPV DNA according to cytological status. The number of hr-HPV 
genotypes was significantly associated with Bethesda grading. Among specimens positive for at least one hr-HPV type, the 
prevalence of multiple infections was 75.3%, with a mean number of 3.5 ± 2.4 different genotypes (range, 2-11). Hr-HPV DNA was 
significantly associated with cytological grade, as were positivity of hr-HPV E6/E7 mRNA, mean S/CO value, and p16 INK4A/Ki-67 
dual staining. Due to sub-optimal quality of samples slides and lack of material, this latter test could be performed in only 74 
patients, and was not interpretable in 10 of these. 
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Diagnostic accuracy of biomarkers.
The diagnosis accuracy of the three tests has been highlighted in the Table 4. For the diagnosis of L-SIL or H-SIL, the identification 
of at least one hr-DNA genotype exhibited a sensitivity (Se) of 0.93, a specificity (Sp) of 0.51, a negative predictive value (NPV) of 
0.88, and a positive predictive value (PPV) of 0.66. High risk HPV E6/E7 mRNA assay had Se, Sp, NPV, and PPV of, respectively, 
0.88, 0.78, 0.87, and 0.80. For p16 INK4A/Ki-67 testing, Se, Sp, NPV, and PPV were 0.64, 0.90, 0.68, and 0.88, respectively. Among 
the 41 patients with no hr-HPV (34.7%), 3 (7.3%) had L-SIL, but none had H-SIL. Of the 23 patients (31.1%) with positive p16
INK4A/Ki-67 testing, 16 (69.6%) had L-SIL, and 3 (13%) had H-SIL. Fig. 1 depicts the triage of our population based on the results of 
these tests. Briefly, a negative result on hr-HPV E6/E7 mRNA test could have avoided subsequent evaluation in one half of the 
population study, as 91.2% of them had no dysplasia and none had H-SIL. On the other hand, in patients positive for hr-HPV E6/E7 
mRNA and p16 INK4A/Ki-67 tests (18.6% of the cohort), a careful examination is required as >85% of them presented with L-SIL or 
H-SIL. The same would apply to the 14.4% of patients with negative p16 INK4A/Ki-67 but carrying HPV-16 or HPV-18 DNA, as this 
combination was associated to dysplasia in ~50% of cases. A last population at low risk of anal dysplasia was identified in this
cohort: patients with negative p16 INK4A/Ki-67, no HPV-16 or HPV-18, and <3 hr-HPV genotypes: only one out of 8 had dysplasia (L-
SIL). To summarize, careful interpretation of hr-HPV E6/E7 mRNA, hr-HPV genotyping and p16 INK4A/Ki-67 tests in this cohort could
accurately classify the risk of dysplasia in 90.8% of patients (Fig. 1). 
DISCUSSION
The increasing incidence of anal cancer in HIV-infected patients, often diagnosed at a late stage, advocates for the implementation 
of systematic or targeted screening of high-risk patients. However, no strategy for anal cancer screening has been validated thus 
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far in this population. Hence, practices vary widely from one cohort to another, as a function of patients will, scientific interest of the 
physicians in charge, and availability of specialized centres qualified for anal cancer screening. In addition, although HRA with 
macroscopically-guided biopsies is highly specific, its sensitivity was recently challenged in a study comparing HRA with a 
combination of different cytological testing (12). Lastly, anal cytology requires pathologist expertise: Inter-agreement assessment 
has been recently found to be moderate-to-good in HIV-infected MSM (14), and the sensitivity and specificity of anal cytology has 
been shown to be 70-93% and 67-92%, respectively, as compared with histological studies from biopsies (15-17). For H-SIL, NPV
of anal cytology were excellent (mean, 85%; range 76-92) in Nathan et al. series. Of note, these authors have shown that the 
sensitivity of anal swab increases with the extension of the disease, and reaches 86% when at least 2 quadrants are involved (17).
Referral to specialized centres performing HRA and cytology may be cost-effective in high-risk population, especially HIV-
infected MSM and HIV-infected women with HPV-related genital lesions (18). However, reliable tests that would allow a pre-
selection of this high-risk population would be most welcome, by decreasing the financial costs of systematic screening, the 
workload for specialized centres, and the number of patients undergoing these invasive, uncomfortable tests. On the one hand, 
biomarkers are costly (approximately 35 to 50 Euros per test); on the other, HRA is somewhat a long procedure (30-45 minutes), 
the assessment of elementary lesions needs a learning curve, and the material is costly (6000 to 18000 Euros).
 Our study suggests that the combination of three biomarkers, hr-HPV E6/E7 mRNA, hr-HPV genotypes and p16INK4A/Ki-67, 
would allow targeted screening of anal dysplasia in HIV-infected patients, by ruling out L-SIL and H-SIL in > 55% of patients. It must 
be outlined that no case of H-SIL would have been overlooked with a strategy that would perform anal cytology and histology only 
in patients positive with either hr-HPV E6/E7 mRNA and/or p16INK4A/Ki-67. By contrast, the guided-biopsies were performed for 
histological studies if lesions were suspected, using acetic acid and Lugol’s solution for better visualization. According to ethical 
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concerns, no biopsy was obtained from patients with normal cytology: in fact, biopsies are somewhat painful and they carry a 
bleeding risk.
We speculated that defining viral profiles and sensitive biomarkers might help to develop diagnostic strategies and tailored 
screening in high-risk groups. We selected candidate biomarkers of viral oncogenicity (hr-HPV DNA, hr-HPV E6/E7 mRNA) and 
cytological abnormalities (p16INK4A/Ki-67), which has already proved useful in screening of cervical cancer. They all can be routinely 
performed and automatized in a multicentre setting. More than 100 HPV genotypes have been linked to anal carcinoma, with
several high-risk subtypes identified, HPV-16 being the most common, although the proportion of non-HPV-16 oncogenic
genotypes has increased in recent series (19). In our study, HPV-16 was found in 35% of swabs positive for hr-HPV, and 6 other
oncogenic genotypes were found in > 10% of patients: HPV 52, 58, 66, 33, 53, and 51. It emphasizes the need of genomic tests 
which detects all hr-HPV genotypes: the APTIMA assay is one of them. For screening purposes, biomarkers must primarily be 
sensitive, if they are to be used as ‘rule-out’ tests. In this regard, the detection of hr-HPV E6/E7 mRNA appears as a suitable test: in 
the study presented herein, one-half of the population had no detection of hr-HPV E6/E7 mRNA, and 91.2% of them had no 
dysplasia (neither L-SIL nor H-SIL). On the contrary, p16INK4A/Ki-67 would not qualify as a good biomarker to rule out anal 
dysplasia, given its low sensitivity (0.64), but would be of interest as a confirmatory test, given its high specificity: only 7.7% of 
patients with positive p16INK4A/Ki-67 had normal cytology. However, not all patients were tested because the material was no longer
available when p16INK4A/Ki67 was retrospectively performed. These preliminary results must be confirmed by a prospective study.
Using three reproducible tests (hr-HPV E6/E7 mRNA, hr-HPV genotype and p16INK4A/Ki-67) with no need for expertise, we 
selected 53 patients (44.9%) who would be candidates for pathologist examination of anal swabs (Fig. 1). Of these, 36 (67.9%) had 
L-SIL or H-SIL on anal cytology and 9 (17%) presented dysplasia on subsequent examination, indicating the need for careful 
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examination of the anal canal with guided biopsies. For the other half of this high-risk HIV-infected population, hr-HPV E6/E7 
mRNA, and hr-HPV genotype could rule out anal dysplasia, and avoid further tests. The diagnostic test performance using a 
combined analysis was lacking in the present study. The aim of the present study was in fact to evaluate the accuracy of each 
biomarker, and the size of the study population does not allow the calculation of predictive values among small subgroups. We tried 
to design a simple algorithm in figure 2 which remains to be tested prospectively among a larger cohort in order to analyse the 
performance of a stepwise combination of tests.  
This study has limitations, especially in the lack of systematic follow-up data in patients with ASC-US or L-SIL. However, 
studies of HPV clearance, co-infections or replacement by new HPV DNA subtypes are in progress in our centre. Changes in 
cytological status over time may be the result of subsequent infectious events, thus the evolution of cytological patterns remains
speculative without concomitant follow-up of HPV status. Monitoring the rate of progression of various stages of anal dysplasia in a 
large HIV-positive cohort, de Pokomandy et al. found no regression of extensive untreated dysplasia, and a dramatic increase in the 
cumulative proportion of subjects with L-SIL or H-SIL at any time point since enrolment in the cohort (9). These data suggest that 
HPV clearance is not a frequent event in HIV-infected patients. Other limitations of our study include its monocentric design, and 
the absence of a validation cohort, as diagnostic algorithms tend to be less accurate when applied in other cohorts. In addition, as
HRA and biopsies were only performed in patients with dysplasia, histological studies were not performed in the whole cohort.
However, to the best of our knowledge, only few studies on the yield of biomarkers for the screening of anal canal cancer in 
high-risk groups have been published (12, 20-22), and only one studied high-risk HPV E6/E7 mRNA and p16INK4A/Ki-67 
immunostaining simultaneously (12). All four studies published to date confirm that these biomarkers may be of interest for anal 
dysplasia screening, although further investigations are required to better define their respective added values. The study presented 
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herein is the second where hr-HPV E6/E7 mRNA was detected with APTIMA assay, which detects 14 hr-HPV, and has been 
associated with improved diagnostic yield for cervical dysplasia (23, 24).
In summary, easy to perform, reproducible and non-invasive biomarkers, such as the identification of high-risk HPV E6/E7 
mRNA, hr-HPV genotypes, and p16INK4A/Ki-67 immunostaining on anal swab may be used for the screening of anal dysplasia in 
HIV-infected patients. In our study, their combination appropriately ruled out L-SIL and H-SIL in >55% of patients.  A simple 
algorithm of a stepwise testing (figure 2) remains to be tested prospectively among a larger cohort. The cost effectiveness 
strategies and the patient compliance need to be clarified in population studies. 
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FIG 1: Triage of human immunodeficiency virus-infected patients screened for anal dysplasia using a combination of 3 
biomarkers 
bold letters: patients with high risk of dysplasia. hr-HPV, High-risk Human Papilloma Virus; ; E6/E7 mRNA : hr-HPV E6/E7 mRNA 
detection on cytology, p16INK4A/Ki-67: p16INK4A/Ki-67 dual staining on cytology
FIG 2 A decision-making algorithm to screen human immunodeficiency virus-infected patients for anal lesions. 
hr-HPV, High-risk Human Papilloma Virus; HRA: High Resolution Anoscopy; E6/E7 mRNA : hr-HPV E6/E7 mRNA detection on 
cytology, p16INK4A/Ki-67: p16INK4A/Ki-67 dual staining on cytology
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TABLE 1 Characteristics of enrolled patients (N=120)
Characteristics Number of patients (%)
Male Gender 108 (90)
Age (years)
20-29 6 (5)
30-39 19 (16)
40-49 51 (43)
50-59 26 (21)
>60 18 (15)
HIV infection stage 
A 72 (60)
B 19 (15.8)
C 28 (23.4)
Undetermined 1 (0.8)
Current cART
Yes 112 (93.3)
No 5 (4.2)
Unknown 3 (2.5)
Nadir of CD4 cell count (cell/mm3)
<200 55 (45.8)
200-400 42 (35)
>400 22 (18.4)
Undetermined 1 (0.8)
HIV load at enrolment (copies/ml)
<40 93 (77.5)
40-100 11 (9.2)
>100 15 (12.5)
Undetermined 1 (0.8)
Smoking
Current and/or past 70 (58.3)
Never 48 (40)
Page 20 of 26
Ac
ce
pte
d M
an
us
cri
pt
20
Undetermined 2 (1.7)
Men who have Sex with Men
Yes 89 (82.4)
No 18 (16.7)
Unknown 1 (0.9)
Injection drug use 8 (6.7)
HIV, human immunodeficiency virus; cART, combination of antiretrovirals
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TABLE 2 High-risk Human Papilloma Virus genotypes according to cytological status, number (%)
Hr-HPV
genotype
NIL
(%, n=49)
ASC-US
(%, n=27)
L-SIL
(%, n=36)
H-SIL
(%, n=6)
Total
(%, n=118)
16* 8(16) 2(7.4) 16(44.4) 5(83.3) 31(25.8)
52* 3(6) 4(14.8) 8(22.2) 3(50) 18(15)
58 6(12) 1(3.7) 10(27.7) 1(16.6) 18(15)
66 4(8) 7(25.9) 5(13.8) 1(16.6) 17(14.2)
33 4(8) 2(7.4) 6(16.6) 2(33.3) 14(11.7)
53 4(8) 1(3.7) 8(22.2) 1(16.6) 14(11.7)
51* 1(2) 2(7.4) 10(27.7) 0(0) 13(10.8)
70 3(6) 3(11.1) 4(11.1) 2(33.3) 12(10)
35* 1(2) 2(7.4) 6(16.6) 2(33.3) 11(9.2)
31* 1(2) 1(3.7) 7(19.4) 1(16.6) 10(8.3)
59 3(6) 0(0) 6(16.6) 1(16.6) 10(8.3)
18 3(6) 3(11.1) 2(5.5) 0(0) 8(6.7)
56 3(6) 1(3.7) 2(5.5) 1(16.6) 7(5.8)
39 3(6) 1(3.7) 2(5.5) 0(0) 6(5)
68 1(2) 2(7.4) 2(5.5) 1(16.6) 6(5)
82 0(0) 2(7.4) 2(5.5) 1(16.6) 5(4.2)
26 0(0) 1(3.7) 2(5.5) 0(0) 3(2.5)
45 0(0) 1(3.7) 1(2.7) 0(0) 2(1.7)
73 1(2) 0(0) 0(0) 0(0) 1(0.8)
85 1(2) 0(0) 0(0) 0(0) 1(0.8)
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Hr HPV High-risk Human Papilloma Virus genotypes are classified according to their prevalence in the study.
* Cytology patterns significantly different with p<0.05; NIL, no intraepithelial lesion; ASC-US, atypical squamous cell of undetermined 
significance; L-SIL, low-grade squamous intraepithelial lesions; H-SIL, high-grade squamous intraepithelial lesion
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TABLE 3 High-risk Human Papilloma Virus genotypes and biomarkers according to cytological status
NIL
n=49
ASC-US
n=27
L-SIL
n=36
H-SIL
n=6
Total
n=118
Mean number of hr-HPV DNA genotypes per patient 1.4 ± 2.1 1.9 ± 1.9 3.8 ± 2.4 4.7 ± 3.1 2.4 ± 2.5
>2 different hr-HPV DNA genotypes, number (%) 8 (16.3) 10 (37) 24 (66.7) 5 (83.3) 47 (39.8)
hr-HPV DNA, number positive (%) 21 (42.9) 17 (63) 33 (91.7) 6 (100) 77 (65.3)
Mean S/Co of hr-HPV E6/E7 mRNA 3.7 ± 7.2 6.5 ± 6.9 14.2 ± 9.2 20.7 ± 10.1 8.3 ± 9.5
hr-HPV E6/E7 mRNA, number positive (%) 11 (22.5) 13 (48.1) 31 (86.1) 6 (100) 60 (50)
p16/Ki-67, number positive/tested (%) 1/13 (7.7) 3/25 (12) 16/31 (44.4) 3/5 (60) 23/74 (31.1)
Cytology patterns are significantly different for each parameter (P<0.0001)
hr-HPV, High-risk Human Papilloma Virus; NIL, no intraepithelial lesion; ASC-US, atypical squamous cell of undetermined significance;
L-SIL, low-grade squamous intraepithelial lesions; H-SIL, high-grade squamous intraepithelial lesion; S/CO, signal-to-cut-off ratio
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TABLE 4 Diagnostic accuracy of biomarkers in the diagnosis of anal dysplasia
Sensitivity Specificity Negative
Predictive 
Value
Positive
Predictive 
Value
hr-HPV DNA genotype 0.93 0.51 0.88 0.66
hr-HPV E6/E7 mRNA 0.88 0.78 0.87 0.80
p16INK4A/Ki-67dual staining 0.64 0.90 0.68 0.88
hr-HPV. High-risk Human Papilloma Virus; 
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